Moreover, multi-omics panels incorporating CTL infiltration, tumor mutation burden, PD-L1 expression, and lncRNA profiles have proven to be practical biomarkers for cancer immunotherapy (Yu et al., 2020b). This evidence concerns the gene CD274 and neoplasm.